Mesenchymal stem cells suppress CD8+ T cell-mediated activation by suppressing natural killer group 2, member D protein receptor expression and secretion of prostaglandin E2, indoleamine 2, 3-dioxygenase and transforming growth factor-β

Clinical and Experimental Immunology

Volumn 178, Issue 3, 2014, Pages 516-524

  Li, Mingfen ^a,b   Sun, Xuyong ^c,e,f   Kuang, Xiaocong ^d   Liao, Yan ^a   Li, Haibin ^c,e,f   Luo, Dianzhong ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF GUANGXI UNIVERSITY OF CHINESE MEDICINE   (China)

^c The 303rd Hospital of PLA   (China)

^d GUANGXI MEDICAL UNIVERSITY   (China)

^e Key Laboratory of Guangxi Basic Chinese Medicine   (China)

^f Department of Organ Transplantation in Guangzhou Military Region ^*  (China)

Author keywords

CD8+ T lymphocytes; Immunosuppression; Mesenchymal stem cell; NKG2D; Soluble factor

Indexed keywords

GAMMA INTERFERON; GRANZYME; HLA ANTIGEN CLASS 1; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 2; KLRK1 PROTEIN, HUMAN; MHC CLASS I-RELATED CHAIN A; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA;

BIOSYNTHESIS; CD8+ T LYMPHOCYTE; CELL COMMUNICATION; CELL CULTURE; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMA CELL; PHYSIOLOGY;

CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CELLS, CULTURED; DINOPROSTONE; GRANZYMES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; TRANSFORMING GROWTH FACTOR BETA;

EID: 84908695393     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12423     Document Type: Article

References (38)

1. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75:389-397.
2. Ramasamy R, Tong CK, Seow HF, Vidyadaran S, Dazzi F. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol 2008; 251:131-136.
3. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105:1815-1822.
4. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood 2008; 111:1327-1333.
5. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009; 113:6576-6583.
6. Ma X, Che N, Gu Z etal. Allogenic mesenchymal stem cell transplantation ameliorates nephritis in lupus mice via inhibition of B-cell activation. Cell Transplant 2013; 22:2279-2290.
7. Maccario R, Podesta M, Moretta A etal. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005; 90:516-525.
8. Le Blanc K, Frassoni F, Ball L etal. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371:1579-1586.
9. Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11:321-334.
10. Sun Y, Tawara I, Toubai T, Reddy P. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res 2007; 150:197-214.
11. Champlin R, Ho W, Gajewski J etal. Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1990; 76:418-423.
12. Amir AL, Hagedoorn RS, van Luxemburg-Heijs SA etal. Identification of a coordinated CD8 and CD4 T cell response directed against mismatched HLA Class I causing severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2012; 18:210-219.
13. Rasmusson I, Uhlin M, Le Blanc K, Levitsky V. Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J Leukoc Biol 2007; 82:887-893.
14. Crop MJ, Korevaar SS, de Kuiper R etal. Human mesenchymal stem cells are susceptible to lysis by CD8(+) T cells and NK cells. Cell Transplant 2011; 20:1547-1559.
15. Markiewicz MA, Carayannopoulos LN, Naidenko OV etal. Costimulation through NKG2D enhances murine CD8+ CTL function: similarities and differences between NKG2D and CD28 costimulation. J Immunol 2005; 175:2825-2833.
16. Azimi N, Jacobson S, Tanaka Y, Corey L, Groh V, Spies T. Immunostimulation by induced expression of NKG2D and its MIC ligands in HTLV-1-associated neurologic disease. Immunogenetics 2006; 58:252-258.
17. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419:734-738.
18. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107:1484-1490.
19. Cerboni C, Ardolino M, Santoni A, Zingoni A. Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells. Blood 2009; 113:2955-2964.
20. Pittenger MF, Mackay AM, Beck SC etal. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-147.
21. Abumaree M, Al Jumah M, Pace RA, Kalionis B. Immunosuppressive properties of mesenchymal stem cells. Stem Cell Rev 2012; 8:375-392.
22. Poggi A, Prevosto C, Massaro AM etal. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J Immunol 2005; 175:6352-6360.
23. Maasho K, Opoku-Anane J, Marusina AI, Coligan JE, Borrego F. NKG2D is a costimulatory receptor for human naive CD8+ T cells. J Immunol 2005; 174:4480-4484.
24. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103:4619-4621.
25. + regulatory T cells. Clin Exp Immunol 2009; 156:149-160.
26. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149:353-363.
27. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76:1208-1213.
28. Ra JC, Shin IS, Kim SH etal. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev 2011; 20:1297-1308.
29. Mouiseddine M, Francois S, Semont A etal. Human mesenchymal stem cells home specifically to radiation-injured tissues in a non-obese diabetes/severe combined immunodeficiency mouse model. Br J Radiol 2007; 80 Special issue no 1:S49-55.
30. Bauer S, Groh V, Wu J etal. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285:727-729.
31. Saez-Borderias A, Guma M, Angulo A, Bellosillo B, Pende D, Lopez-Botet M. Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus. Eur J Immunol 2006; 36:3198-3206.
32. Rajasekaran K, Xiong V, Fong L, Gorski J, Malarkannan S. Functional dichotomy between NKG2D and CD28-mediated co-stimulation in human CD8+ T cells. PLOS ONE 2010; 5:e12635.
33. Ogasawara K, Hamerman JA, Hsin H etal. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 2003; 18:41-51.
34. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 2008; 180:7249-7258.
35. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31:413-441.
36. Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2, 3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 2005; 106:2375-2381.
37. Liu XJ, Zhang JF, Sun B etal. Reciprocal effect of mesenchymal stem cell on experimental autoimmune encephalomyelitis is mediated by transforming growth factor-beta and interleukin-6. Clin Exp Immunol 2009; 158:37-44.
38. Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol 2010; 12:7-13.